Eighty patients receiving hematological stem cell transplantation (HCT) with a preparative regimen consisting of total body irradiation (12. monly after doses of 180 mg/kg or more, and signs and symptoms of congestive heart failure (CHF) occur within the initial 2 or 3 weeks after hematological stem cell transplantation (HCT).
monly after doses of 180 mg/kg or more, and signs and symptoms of congestive heart failure (CHF) occur within the initial 2 or 3 weeks after hematological stem cell transplantation (HCT). 1, 2 Many patients receive anthracycline antibiotics, which impair cardiac function in a dose-dependent manner. 3 It is unclear whether anthracycline given prior to a transplant increases the risk of CY-induced cardiac toxicity and whether the occurrence of cardiac toxicity is correlated with a reduction in left ventricular ejection fraction (EF) before HCT. One clinical study showed that a reduced EF but cumulative pretransplant anthracycline dose has a tendency to provoke severe cardiac toxicity. 4 Others observed that severe cardiac toxicity is not predicted by EF value before HCT. 5 In these studies, a variety of preparative regimens was used, and some regimens did not contain CY, which was shown to be a significant risk factor for the development of cardiac toxicity. 6 These factors make it impossible to assess whether cardiac toxicity is directly influenced by the preparative regimen.
We retrospectively analyzed the development of cardiac complications in patients who had undergone HCT with the same preparative regimen consisting of CY, thiotepa, and total body irradiation (TBI) at our institution between 1994 and 1999, and found a significant correlation between EF before HCT and the development of cardiac complications.
Materials and methods

Patients
Eighty-six adults underwent marrow transplantation for hematological malignancies between May 1994 and April 1999 at our institution. To analyze clearly the effect of conditioning regimen on cardiac function, we studied 80 patients who received the same conditioning regimen and excluded six patients who received other conditioning regimens. The conditioning regimen consisted of intravenous thiotepa, 200 mg/m 2 /day for 2 consecutive days (total 400 mg/m 2 ); intravenous CY, 2250 mg/m 2 /day for 2 consecutive days (total 4500 mg/m 2 ); and TBI given in five fractions of 2.5 Gy for 3 days (total 12.5 Gy). For patients more than 40 years old, the CY dose was reduced to 2000 mg/m 2 /day for 2 consecutive days (total 4000 mg/m 2 ). Patient characteristics are listed in Table 1 . Acute GVHD prophylaxis consisted of short-term methotrexate and cyclosporin A in all patients but two identical twin recipients. Cumulative doses of anthracycline were obtained from patient records and converted to the corresponding doses of adriamycin, with a scale of inducing CHF at 5-10% incidence [7] [8] [9] [10] [11] [12] (Table 2 ). For example, daunorubicin is considered to be half as toxic as doxorubicin because a 5-10% incidence of developing congestive heart failure was reported by a total dose of 500-600 mg/m 2 of doxorubicin or 900-1000 mg/m 2 of daunorubicin. We calculated as follows: cumulative dose of anthracycline
As the 16% of chemotherapy cycles given before an HCT did not include anthracycline, the number of courses of myelosuppressive chemotherapy was also examined. Maintenance therapy and treatment of CML, such as interferon, hydroxyurea and busulfan, were not taken into account in the analysis.
EF at rest was recorded by two-dimensional echocardiography before preconditioning, and at day 100 after the HCT. When patients were considered to have cardiac dysfunction, echocardiography was also performed. We choose this method rather than radionuclide ventriculography to estimate the EF because echocardiography can be done readily and immediately in cases of need although radionuclide ventriculography is considered to be more reliabile Table 2 Total dose for inducing congestive heart failure at 5-10% incidence
Drugs
Total dose Ref. compared to echocardiography. Cardiac toxicity was graded using the system previously described by Bearman et al. 4 
Statistics
The relationship of anthracycline dose and EF was examined by simple linear regression. Pretransplant and posttransplant EF were compared using paired t-test. To compare EF in the two groups according to cumulative pretransplant anthracycline dose or number of chemotherapy treatments, the unpaired t-test was used. Incidences of major cardiac toxicity were compared using Fisher's exact test.
Results
Ejection fractions
EF before the HCT decreased with increasing pretransplant anthracycline doses (r 0.61 Ϯ 0.09, P = 0.0010). A significant difference was also found in EF after HCT (0.67 Ϯ 0.06 vs 0.60 Ϯ 0.08, P = 0.0066) (Figure 2) . To evaluate the effect of antitumor drugs other than anthracyclines, we compared EF in these patients by number of myelosuppressive chemotherapy treatments given before HCT. Fourteen patients who underwent more than or equal to six courses of chemotherapy showed a decreased EF before HCT compared to 33 patients with less than six courses (0.67 Ϯ 0.05 vs 0.63 Ϯ 0.09, P = 0.03). Similarly, a decreased EF at day 100 after HCT was observed in patients given six or more courses of chemotherapy (0.66 Ϯ 0.06 vs 0.61 Ϯ 0.08, P = 0.03) (Figure 3) .
To study the effect of CY used in conditioning on cardiac function after HCT, we compared EF before HCT and at day 100 after HCT in 53 patients who were studied by echocardiography. There were no differences between EF before HCT and on day 100 (0.66 Ϯ 0.067 vs 0.65 Ϯ 0.074, P = 0.39). This was not affected by the cumulative anthracycline dose and number of myelosuppressive chemotherapy courses given before the HCT (Figures 2 and 3) . Ant. = anthracycline; CHF = congestive heart failure; PE = pericardial effusion; VF = ventricular fibrillation; CTX = number of chemotherapy.
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Cardiac toxicity
Three patients developed grade III or IV cardiac toxicity (Table 3) . Cardiac toxicity was characterized by CHF in all patients. UPN 76 and UPN 146 underwent echocardiography on days 21 and 5, which revealed the EF to be 0.20 and 0.22, respectively. UPN 76 developed ventricular fibrillation and died on day 142. UPN 146 died of CHF on day 9. UPN 89 developed a pericardial tamponade yielding more than 600 ml of fluid on day 30 with symptoms of CHF, which resolved on day 56, and died of acute GVHD on day 70. Two of three patients received more than 300 mg/m 2 of cumulative anthracycline and underwent more than six chemotherapy treatments. However, the other patient (UPN 146) received only two courses of chemotherapy, which contained 139 mg/m 2 of anthracycline. The pretransplant EFs of these three patients were 0.55, 0.55 and 0.47, respectively. Three of seven patients (43%), whose pretransplant EFs were less than or equal to 0.55, developed grade III or IV cardiac toxicity compared with none of 83 patients (0%) whose pretransplant EFs were more than 0.55 (P = 0.00026). None of these three patients had any additional factors which may have contributed to the cardiac problems, such as severe infections.
Discussion
In this study, a decreased EF before HCT was significantly associated with the development of grade III or IV cardiac toxicity. Bearman et al 4 reported that two of 10 patients (20%) whose pretransplant EF was less than 0.50, and five of 116 patients (4%) whose pretransplant EF was greater than or equal to 0.50, developed severe cardiac toxicity (P = 0.096). Hertenstein et al 5 also reported that one of 22 patients (5%) whose pretransplant EF was greater than 0.55 and two of 148 patients (1%) whose pretransplant EF was greater than 0.55 developed severe cardiac toxicity (P = 0.34). In these studies, a variety of preparative regimens was used. In our study, we used the same preparative regimen containing CY. This may have resulted in the different incidence of severe cardiac toxicity in patients with a reduced EF. We could not exclude the possibility that thiotepa used in our conditioning regimen might affect the incidence of the severe cardiac toxicity although thiotepa has not been reported to have a toxic cardiac effect itself or to increase CY-induced cardiac toxicity.
Several factors, such as cumulative dose of anthracycline, combination chemotherapy, mediastinal radiotherapy, previous coronary disease and transfusion-associated iron overload, may contribute to cardiac injury. 13 None of our patients had previously received mediastinal radiation or been found to have coronary disease. We showed that an increased cumulative dose of anthracycline and multiple chemotherapy treatments, which should reflect the use of combination chemotherapy and the frequency of transfusion, correlated with decreased EF before HCT. However, development of severe cardiac toxicity with HCT could not be predicted because one of three patients who developed severe cardiac toxicity received only two courses of chemotherapy with 139 mg/m 2 of anthracycline. This patient was 17 years old, however, and it has been shown that cardiac toxicity develops readily in young patients with a low dose of anthracyclines. 7 CY-induced cardiac toxicity might also develop easily in young patients.
We also showed that there were no differences between the EF before HCT and EF at day 100. This result was consistent with Baello et al's 14 study in that no significant change in EF before or after allogeneic BMT was found with a preparative regimen containing a high dose of CY (90 mg/kg). In our patient who developed severe cardiac toxicity at day 14 after HCT, the EF decreased from 0.55 before HCT to 0.41 at day 100 after HCT. This result means that once severe cardiac toxicity has developed, toxicity may be irreversible.
In conclusion, patients with a reduced EF before HCT were at significant risk of severe cardiac toxicity. An increased cumulative dose of anthracycline and number of chemotherapy treatments correlated with a decrease in EF but were not significant predictors for severe cardiac toxicity. Therefore, we recommend that EF should be recorded in all patients being considered for HCT. Patients with an EF less than or equal to 0.55 should be considered for HCT with reduced doses of the preparative regimen, such as are given with a mini-transplant, to avoid cardiac toxicity.
